Batches of Latuda tablets by CNX Therapeutics to arrive without barcodes

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for Latuda film-coated tablets by CNX Therapeutics.

CNX Therapeutics have notified the MHRA that a few batches of Latuda film-coated tablets will be released without EAN barcodes on the cartons. The batch numbers and the expiry dates are present and clearly visible on the cartons and on the blisters.

Although fully in line with the Marketing Authorisation, the absence of the barcodes may lead to queries as these may sometimes be used for stock control and automated dispensing.

This stock has not yet been distributed, however due to the consideration for stock control and automated dispensing, this notification is being shared in advance of distribution from CNX Therapeutics to wholesalers and pharmacies. The expected distribution dates for these batches will take place between April 2022 and July 2022.

Product description

Latuda 18.5mg film-coated tablets PLGB 19635/00035

Latuda 37mg film-coated tablets PLGB 19635/0004

Latuda 74 mg film-coated tablets PLGB 19635/0005

Active Pharmaceutical Ingredient: Lurasidone (as lurasidone hydrochloride)

Wholesalers and healthcare professionals are urged to refer to the batch number and expiry date printed on the carton for stock control and dispensing. The impacted products are within specification and there is no issue with product quality and are not being recalled.